For example, it was found that the compound repressed the expression/secretion of different angiogenic factors (including VEGF and PDGF) and matrix-degrading enzymes (such as urokinase-type plasminogen activator (uPA), MMP-2, and MMP-9) in human bladder cancer cells, upregulating angiogenesis inhibitor levels (such as plasminogen activator inhibitor-1 (PAI-1), angiostatin, endostatin, and thrombospondin-1 (TSP-1)) [75]. The gene discussed is PLAU; the disease is urinary bladder cancer.